Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
NEW YORK, July 6, 2012 (GLOBE NEWSWIRE) -- Shareholders of Tibet Pharmaceuticals, Inc. ("Tibet" or the "Company") (OTCBB:TBET) are reminded of the securities class action filed against Tibet and...
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed in the United States District Court for the District Court of the Virgin Islands on behalf of...
Glancy Binkow & Goldberg LLP announces that a class action lawsuit has been filed in the United States District Court for the District Court of the Virgin Islands on behalf of...
NEW YORK, June 8, 2012 (GLOBE NEWSWIRE) -- Pomerantz Haudek Grossman & Gross LLP has filed a federal securities class action (12 Civ. 4511) in United States District Court, Southern District of...
Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing In Tibet Pharmaceuticals Inc. To Contact The Firm PR Newswire NEW YORK, June 1, 2012 NEW YORK, June 1, 2012...
Bronstein, Gewirtz & Grossman, LLC Announces That A Class Action Has Been Filed Against Tibet Pharmaceuticals, Inc. PR Newswire NEW YORK, May 31, 2012 NEW YORK, May 31, 2012 /PRNewswire/...
The Rosen Law Firm, P.A. today announced that it has filed a class action lawsuit on behalf of investors who purchased the securities of Tibet Pharmaceuticals, Inc. (“Tibet...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 1.0E-6 | 0.0001 | 1.0E-6 | 6600 | 1.0E-6 | CS |
| 4 | 0 | 0 | 1.0E-6 | 0.0001 | 1.0E-6 | 6600 | 1.0E-6 | CS |
| 12 | 0 | 0 | 1.0E-6 | 0.0001 | 1.0E-6 | 4200 | 1.0E-6 | CS |
| 26 | 0 | 0 | 1.0E-6 | 0.0001 | 1.0E-6 | 2183 | 1.0E-6 | CS |
| 52 | 0 | 0 | 1.0E-6 | 0.0001 | 1.0E-6 | 2110 | 1.0E-6 | CS |
| 156 | -9.9E-5 | -99 | 0.0001 | 0.0001 | 1.0E-6 | 2702 | 4.248E-5 | CS |
| 260 | -9.9E-5 | -99 | 0.0001 | 0.1 | 1.0E-6 | 48442 | 0.01536219 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
